Article
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Cancer research - 1 May 2009
Hay Trevor, Matthews James R, Pietzka Lucie, Lau Alan, Cranston Aaron, Nygren Anders O H, Douglas-Jones Anthony, Smith Graeme C M, Martin Niall M B, O'Connor Mark, Clarke Alan R
Abstract excerpt
Germ-line heterozygosity of the BRCA2 gene in women predisposes to breast and ovarian cancers. Successful therapies targeted specifically at these neoplasms have thus far remained elusive. Recent studies in mice have shown that inhibition of poly(ADP-ribose) polymerase-1 (PARP-1) targets cells lacking Brca2 and xenografts derived from BRCA2-deficient ES cells or Chinese hamster ovary cells. We set out to develop...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.